



Figure 1. Participant disposition. *Two participants who were randomized to the clesrovimab 20-mg group actually received a 50-mg dose of clesrovimab and were included in the 50-mg clesrovimab group for safety, pharmacokinetic, serum neutralizing antibody, and antidrug antibodies analyses.